Your browser doesn't support javascript.
loading
Recent developments in nitric oxide donor drugs.
Miller, M R; Megson, I L.
Affiliation
  • Miller MR; Centre for Cardiovascular Science, University of Edinburgh, Queen's Medical Research Institute, Edinburgh, UK.
Br J Pharmacol ; 151(3): 305-21, 2007 Jun.
Article in En | MEDLINE | ID: mdl-17401442
ABSTRACT
During the 1980s, the free radical, nitric oxide (NO), was discovered to be a crucial signalling molecule, with wide-ranging functions in the cardiovascular, nervous and immune systems. Aside from providing a credible explanation for the actions of organic nitrates and sodium nitroprusside that have long been used in the treatment of angina and hypertensive crises respectively, the discovery generated great hopes for new NO-based treatments for a wide variety of ailments. Decades later, however, we are still awaiting novel licensed agents in this arena, despite an enormous research effort to this end. This review explores some of the most promising recent advances in NO donor drug development and addresses the challenges associated with NO as a therapeutic agent.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cardiovascular Physiological Phenomena / Nitric Oxide Donors Limits: Animals / Humans Language: En Journal: Br J Pharmacol Year: 2007 Type: Article Affiliation country: United kingdom

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cardiovascular Physiological Phenomena / Nitric Oxide Donors Limits: Animals / Humans Language: En Journal: Br J Pharmacol Year: 2007 Type: Article Affiliation country: United kingdom